A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs

Trial Profile

A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs FLT-3 ligand (Primary) ; Plerixafor (Primary)
  • Indications Stem cell mobilisation
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 30 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top